- Home
- Publications
- Publication Search
- Publication Details
Title
Tocilizumab (Actemra)
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume 13, Issue 9, Pages 1972-1988
Publisher
Informa UK Limited
Online
2017-08-26
DOI
10.1080/21645515.2017.1316909
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents
- (2016) Balázs Vezér et al. CURRENT MEDICAL RESEARCH AND OPINION
- Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
- (2016) Peter M Villiger et al. LANCET
- Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis
- (2016) Naoki Iwamoto et al. Modern Rheumatology
- BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids: Table 1
- (2016) Julia Flint et al. RHEUMATOLOGY
- FRI0280 Efficacy and Safety of Tocilizumab as First Line Therapy in Patients with Recent Polymyalgia Rheumatica (PMR): Results of the First Longitudinal Prospective Study (Tenor)
- (2015) V. Devauchelle et al. ANNALS OF THE RHEUMATIC DISEASES
- Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
- (2015) Kevin Klein et al. DRUG SAFETY
- Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan
- (2015) K. Yamamoto et al. JOURNAL OF RHEUMATOLOGY
- Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
- (2014) Hermine I Brunner et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions
- (2014) Norihiro Nishimoto et al. Modern Rheumatology
- IL-6 biology: implications for clinical targeting in rheumatic disease
- (2014) Leonard H. Calabrese et al. Nature Reviews Rheumatology
- A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
- (2013) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review
- (2013) Noémie Abisror et al. AUTOIMMUNITY REVIEWS
- Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
- (2013) M. C. Genovese et al. JOURNAL OF RHEUMATOLOGY
- Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan
- (2013) T. Koike et al. JOURNAL OF RHEUMATOLOGY
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis
- (2013) Y Hishitani et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
- (2013) Atsushi Ogata et al. ARTHRITIS CARE & RESEARCH
- Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis
- (2012) Claire Immediato Daïen et al. ANNALS OF THE RHEUMATIC DISEASES
- Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
- (2012) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
- (2012) Stefan Rose-John International Journal of Biological Sciences
- Giant coronary artery aneurysms in juvenile polyarteritis nodosa: a case report
- (2012) Therese L Canares et al. Pediatric Rheumatology
- Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis
- (2012) E. Choy RHEUMATOLOGY
- Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study
- (2012) Michael E. Weinblatt et al. ARTHRITIS CARE & RESEARCH
- Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review
- (2011) Taras Gout et al. CLINICAL RHEUMATOLOGY
- IL-6/IL-6 receptor system and its role in physiological and pathological conditions
- (2011) Masahiko Mihara et al. CLINICAL SCIENCE
- Australasian Faculty of Occupational & Environmental Medicine - Posters
- (2011) INTERNAL MEDICINE JOURNAL
- Inhibition of Classic Signaling Is a Novel Function of Soluble Glycoprotein 130 (sgp130), Which Is Controlled by the Ratio of Interleukin 6 and Soluble Interleukin 6 Receptor
- (2011) Christoph Garbers et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Indirect comparison of biological treatments in refractory rheumatoid arthritis
- (2011) M. Gallego-Galisteo et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Gp130-Dependent Release of Acute Phase Proteins Is Linked to the Activation of Innate Immune Signaling Pathways
- (2011) Maren Luchtefeld et al. PLoS One
- Treatment of refractory adult-onset still’s disease with tocilizumab: report of two cases and review of the literature
- (2011) Rene Thonhofer et al. RHEUMATOLOGY INTERNATIONAL
- Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis
- (2010) C. Salliot et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
- (2010) Gabor G. Illei et al. ARTHRITIS AND RHEUMATISM
- Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
- (2010) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- IL-6: Regulator of Treg/Th17 balance
- (2010) Akihiro Kimura et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- A Case of Multicentric Castleman's Disease Having Lung Lesion Successfully Treated with Humanized Anti-interleukin-6 Receptor Antibody, Tocilizumab
- (2010) Tomoaki Higuchi et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica
- (2010) K. HAGIHARA et al. JOURNAL OF RHEUMATOLOGY
- Certolizumab Pegol
- (2010) Niti Goel et al. mAbs
- Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs
- (2010) Gert J.D. Bergman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis
- (2010) Srinivasan Srirangan et al. Therapeutic Advances in Musculoskeletal Disease
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
- (2009) G. Jones et al. ANNALS OF THE RHEUMATIC DISEASES
- Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
- (2009) Merete Lund Hetland et al. ARTHRITIS AND RHEUMATISM
- Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab
- (2009) Kazuko Matsumoto et al. CLINICAL RHEUMATOLOGY
- Tocilizumab: The first interleukin-6-receptor inhibitor
- (2008) Anthony Sebba AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
- (2008) N Nishimoto et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- The Impact of PEGylation on Biological Therapies
- (2008) Francesco M Veronese et al. BIODRUGS
- Serum from children with polyarticular juvenile idiopathic arthritis (pJIA) inhibits differentiation, mineralization and may increase apoptosis of human osteoblasts “in vitro”
- (2008) Valéria F. Caparbo et al. CLINICAL RHEUMATOLOGY
- Interleukin-6 Directly Inhibits Osteoclast Differentiation by Suppressing Receptor Activator of NF-κB Signaling Pathways
- (2008) Fumio Yoshitake et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now